International Journal of High Risk Behaviors and Addiction

Published by: Kowsar

Fast Effect of Buprenorphine on Opioid-dependent Patients with Suicidal Ideation: A Novel Approach

Jamshid Ahmadi 1 , * and Mina Sefidfard Jahromi 1
Authors Information
1 Substance Abuse Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • International Journal of High Risk Behaviors and Addiction: June 2018, 7 (2); e57510
  • Published Online: January 8, 2018
  • Article Type: Research Article
  • Received: March 4, 2017
  • Revised: October 2, 2017
  • Accepted: November 12, 2017
  • DOI: 10.5812/ijhrba.57510

To Cite: Ahmadi J, Sefidfard Jahromi M. Fast Effect of Buprenorphine on Opioid-dependent Patients with Suicidal Ideation: A Novel Approach, Int J High Risk Behav Addict. 2018 ; 7(2):e57510. doi: 10.5812/ijhrba.57510.

Abstract
Copyright © 2018, International Journal of High Risk Behaviors and Addiction. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Centers for Disease C; Prevention. Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria--worldwide, 2010-2012. MMWR Morb Mortal Wkly Rep. 2013;62(1):5-8. [PubMed: 23302816].
  • 2. Olfson M, Gameroff MJ, Marcus SC, Greenberg T, Shaffer D. Emergency treatment of young people following deliberate self-harm. Arch Gen Psychiatry. 2005;62(10):1122-8. doi: 10.1001/archpsyc.62.10.1122. [PubMed: 16203957].
  • 3. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14(8):1127-31. doi: 10.1017/S1461145711000629. [PubMed: 21557878].
  • 4. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646. doi: 10.1136/bmj.f3646. [PubMed: 23814104].
  • 5. George MS, Raman R, Benedek DM, Pelic CG, Grammer GG, Stokes KT, et al. A two-site pilot randomized 3 day trial of high dose left prefrontal repetitive transcranial magnetic stimulation (rTMS) for suicidal inpatients. Brain Stimul. 2014;7(3):421-31. doi: 10.1016/j.brs.2014.03.006. [PubMed: 24731434].
  • 6. Fink M, Kellner CH, McCall WV. The role of ECT in suicide prevention. J ECT. 2014;30(1):5-9. doi: 10.1097/YCT.0b013e3182a6ad0d. [PubMed: 24091903].
  • 7. Striebel JM, Kalapatapu RK. The anti-suicidal potential of buprenorphine: a case report. Int J Psychiatry Med. 2014;47(2):169-74. doi: 10.2190/PM.47.2.g. [PubMed: 25084802].
  • 8. Yovell Y, Bar G, Mashiah M, Baruch Y, Briskman I, Asherov J, et al. Ultra-Low-Dose Buprenorphine as a Time-Limited Treatment for Severe Suicidal Ideation: A Randomized Controlled Trial. Am J Psychiatry. 2016;173(5):491-8. doi: 10.1176/appi.ajp.2015.15040535. [PubMed: 26684923].
  • 9. Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WJ. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl). 2004;172(4):463-70. doi: 10.1007/s00213-003-1680-y. [PubMed: 14727002].
  • 10. Drug Enforcement Administration DOJ. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule. Fed Regist. 2002;67(194):62354-70. [PubMed: 12369590].
  • 11. Ahmadi J. The effect of buprenorphine on the reduction of cannabis and heroin craving and suicidal thoughts: a new finding. Insights Biomed. 2016;1:2.
  • 12. Ahmadi J. Fast Treatment of Methamphetamine Related Anxiety and Depressive Disorders: A Novel Approach. J Addict Med Ther Sci. 2016:1-3. doi: 10.17352/2455-3484.000011.
  • 13. Ahmadi J. Instant Detoxification of Heroin with High Dose of Buprenorphine. J Addict Prevent. 2016;4(1):3.
  • 14. Gracer R. The Buprenorphine Effect on Depression. The National Alliance of Advocates for Buprenorphine Treatment (NAABT). 2007.
  • 15. Sadock BJ, Sadock VA. Kaplan and Sadock's synopsis of psychiatry: Behavioral sciences/clinical psychiatry. Lippincott Williams & Wilkins; 2011.
  • 16. Gerra G, Leonardi C, D'Amore A, Strepparola G, Fagetti R, Assi C, et al. Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(2):265-72. doi: 10.1016/j.pnpbp.2005.10.007. [PubMed: 16309810].
  • 17. Ipser JC, Terburg D, Syal S, Phillips N, Solms M, Panksepp J, et al. Reduced fear-recognition sensitivity following acute buprenorphine administration in healthy volunteers. Psychoneuroendocrinology. 2013;38(1):166-70. doi: 10.1016/j.psyneuen.2012.05.002. [PubMed: 22651957].
  • 18. Maremmani AG, Rovai L, Pani PP, Pacini M, Lamanna F, Rugani F, et al. Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts? Ann Gen Psychiatry. 2011;10:17. doi: 10.1186/1744-859X-10-17. [PubMed: 21569624].
  • 19. Falcon E, Maier K, Robinson SA, Hill-Smith TE, Lucki I. Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. Psychopharmacology (Berl). 2015;232(5):907-15. doi: 10.1007/s00213-014-3723-y. [PubMed: 25178815].
  • 20. Beck AT, Steer RA, Ranieri WF. Scale for suicide ideation: Psychometric properties of a self-report version. J Clin Psychol. 1988;44(4):499-505. doi: 10.1002/1097-4679(198807)44:4<499::aid-jclp2270440404>3.0.co;2-6.
  • 21. Soyka M. New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. Substance Abuse Rehabil. 2015;6:1-14.
  • 22. Mintzer MZ. Effects of opioid pharmacotherapy on psychomotor and cognitive performance: a review of human laboratory studies of methadone and buprenorphine. Heroin Addict Relat Clin Probl. 2007;9(1):5-24.
  • 23. Darke S, Ross J. Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug Alcohol Depend. 1997;48(2):135-41. [PubMed: 9363413].
  • 24. Ross J, Teesson M, Darke S, Lynskey M, Ali R, Ritter A, et al. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005;24(5):411-8. doi: 10.1080/09595230500286039. [PubMed: 16298835].
  • 25. Rounsaville BJ, Weissman MM, Crits-Christoph K, Wilber C, Kleber H. Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome. Arch Gen Psychiatry. 1982;39(2):151-6. [PubMed: 7065829].
  • 26. Savant JD, Barry DT, Cutter CJ, Joy MT, Dinh A, Schottenfeld RS, et al. Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment. Drug Alcohol Depend. 2013;127(1-3):243-7. doi: 10.1016/j.drugalcdep.2012.06.020. [PubMed: 22771144].
  • 27. Schäfer I, Fischer M, Reimer J, Karow A, Haasen C. Significance of psychiatric comorbidity for the outcome of maintenance treatment – a review of the literature. Ment Health Substance Use. 2011;4(1):62-71. doi: 10.1080/17523281.2011.533452.
  • 28. Strain EC. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain. 2002;18(4 Suppl):S14-27. [PubMed: 12479251].
  • 29. Merikangas KR, Mehta RL, Molnar BE, Walters EE, Swendsen JD, Aguilar-Gaziola S, et al. Comorbidity of substance use disorders with mood and anxiety disorders. Addict Behav. 1998;23(6):893-907. doi: 10.1016/s0306-4603(98)00076-8.
  • 30. Merikangas KR, Zhang H, Avenevoli S, Acharyya S, Neuenschwander M, Angst J, et al. Longitudinal trajectories of depression and anxiety in a prospective community study: the Zurich Cohort Study. Arch Gen Psychiatry. 2003;60(10):993-1000. doi: 10.1001/archpsyc.60.9.993. [PubMed: 14557144].
  • 31. Moggi F. Etiological theories on the relationship of mental disorders and substance use disorders. Suchtmed. 2013;15:327–333.
  • 32. Soyka M. Affective and anxiety disorders and drug addiction. Suchtmed. 2013;15:341-8.
  • 33. Darke S, Mills K, Teesson M, Ross J, Williamson A, Havard A. Patterns of major depression and drug-related problems amongst heroin users across 36 months. Psychiatry Res. 2009;166(1):7-14. doi: 10.1016/j.psychres.2007.12.007. [PubMed: 19215987].
  • 34. Torrens M, Martínez-Sanvisens D, Martínez-Riera R, Bulbena A, Szerman N, Ruiz P. Dual Diagnosis. Addict Disord Their Treat. 2011;10(2):50-9. doi: 10.1097/ADT.0b013e318215f322.
  • 35. Rothman RB, Gorelick DA, Heishman SJ, Eichmiller PR, Hill BH, Norbeck J, et al. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. J Subst Abuse Treat. 2000;18(3):277-81. [PubMed: 10742642].
  • 36. Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15(1):49-57. [PubMed: 7714228].
  • 37. Emrich HM, Vogt P, Herz A, Kissling W. Antidepressant effects of buprenorphine. Lancet. 1982;2(8300):709. [PubMed: 6126640].
  • 38. Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl). 2010;210(2):121-35. doi: 10.1007/s00213-010-1825-8. [PubMed: 20352414].
  • 39. Ahmadi J, Razeghian Jahromi L. Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial. Trials. 2017;18(1):259. doi: 10.1186/s13063-017-2007-3. [PubMed: 28587620].
  • 40. Ahmadi J, Dastgheib SA, Pridmore S. Buprenorphine in the Treatment of Severe Major Depression with Severe Suicidal Temptations. Glob J Addict Rehabil Med. 2017;1(5):1-3.
  • 41. Ahmadi J. Off label Administration of Buprenorphine in the Treatment of Major Depression. J Depress Anxiety. 2017;6:263.
  • 42. Ahmadi J. Highdose of Buprenorphine in the Treatment of Refractory Major Depression with Severe Suicidal Tendencies. J Addict Dependence. 2017;3(1):1-3. doi: 10.15436/2471-061x-17-033.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments